Ticagrelor is no better than aspirin at preventing cardiovascular events after acute stroke or TIA, study findsBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2654 (Published 12 May 2016) Cite this as: BMJ 2016;353:i2654
- Susan Mayor
Ticagrelor, a direct acting antiplatelet agent, is no more effective than aspirin at preventing recurrent stroke, myocardial infarction, or death in patients who have an ischaemic stroke or transient ischaemic attack (TIA), a randomised trial has shown.1
The risk of a further ischaemic event is high in the first 90 days after a stroke or TIA, so aspirin is commonly used to reduce thrombotic risk. But a risk …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial